This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
7 Best Leveraged ETF Areas of Last Week
by Sanghamitra Saha
Wall Street was upbeat last week. News of zero new cases in China, U.S. FDA's full approval of Pfizer-BioNTech Covid-19 vaccine and no new flare-up in taper talks led to the gains.
The Zacks Analyst Blog Highlights: Pfizer, AT&T, Intuit, Automatic Data Processing and Booking Holdings
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, AT&T, Intuit, Automatic Data Processing and Booking Holdings
Top Analyst Reports for Pfizer, AT&T & Intuit
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), AT&T Inc. (T), and Intuit Inc. (INTU).
DAL Ups Unvaccinated Health Costs: Other Airlines to Follow?
by Maharathi Basu
Delta Air's (DAL) decision is aimed at addressing the financial perils the company might grapple with pertaining to unvaccinated employees.
Sorrento's (SRNE) COVID Vaccine Effective in Pre-Clinical Study
by Zacks Equity Research
Sorrento (SRNE) announces data from pre-clinical study for its investigational mRNA COVID vaccine. The company also in-licensed rights to highly potent main protease inhibitors against COVID variants.
Ascendis (ASND) Rallies on First FDA-Approved Drug Skytrofa
by Zacks Equity Research
Ascendis' (ASND) Skytrofa gets FDA approval for treating growth failure in pediatric patients. The drug is also the first FDA-approved product in the company's portfolio.
Why Is Pfizer (PFE) Up 10.7% Since Last Earnings Report?
by Zacks Equity Research
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pfizer (PFE) Inks Deal With Eurofarma to Make COVID-19 Vaccine
by Zacks Equity Research
Pfizer (PFE) and partner BioNTech ink a collaboration deal with Brazil's Eurofarma for manufacturing and supplying their COVID-19 vaccine, Comirnaty, in Latin America.
5 Leveraged/Inverse ETFs Sizzling This Summer
by Sweta Killa
Amid bouts of volatility and uncertainty, the Wall Street is sizzling this summer buoyed by solid corporate earnings growth and recovering economy.
Pharma Stock Roundup: PFE's COVID Jab Full Approval by FDA, JNJ's Booster Data
by Kinjel Shah
FDA approves Pfizer's (PFE) BLA for COVID-19 vaccine, Comirnaty. J&J (JNJ) released data supporting use of the booster shot.
Should Invesco S&P Ultra Dividend Revenue ETF (RDIV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RDIV
ETFs to Gain on Renewed Market Optimism
by Sweta Jaiswal, FRM
The Wall Street rally is expected to continue on optimism surrounding the vaccine full FDA approval and chances of peaking delta variant cases, which point to recovery from the pandemic-induced slump.
Airline Stock Roundup: LUV's Tentative Labor Deal, DAL's Fleet Upgrade & More
by Maharathi Basu
Southwest Airlines (LUV) inks a tentative labor deal on its customer-service employees. Delta (DAL) places an order for more A321neo jets.
Biotech Stock Roundup: REGN, MRNA Offer COVID-19 Updates, TBPH Down on Study Update
by Zacks Equity Research
Regulatory and pipeline updates from Regeneron (REGN) and Moderna (MRNA), among others have been in focus in the biotech industry over the past week.
Pfizer (PFE), BioNTech Seek Full Approval for COVID Jab Booster
by Zacks Equity Research
The booster dose of Pfizer (PFE)/BioNTech's (BNTX) mRNA-based COVID-19 vaccine, Comirnaty dose induced significant SARS-CoV-2 neutralizing antibody titers in phase III study.
Tap the Red Hot Biotech Sector With These 2 Leveraged ETFs
by Sweta Killa
Investors could easily tap the bullish trend by considering a near-term long on the biotech sector.
J&J (JNJ) Reports Positive Interim Data on COVID Booster Jab
by Zacks Equity Research
The booster dose of J&J's (JNJ) single-shot COVID-19 vaccine achieves rapid and robust increase in spike-binding antibodies in previously vaccinated people with the initial dose.
Moderna (MRNA) Seeks Full FDA Approval for COVID-19 Vaccine
by Zacks Equity Research
Moderna (MRNA) completes rolling submission of BLA to the FDA seeking full approval of its COVID-19 vaccine candidate, mRNA-1273, in the United States.
5 Tech ETFs Outperforming the Market This Year
by Sweta Killa
The technology sector has regained strong momentum lately, making it one of the outperforming sectors of this year.
ETFs to Rise on Full FDA Approval for Pfizer COVID-19 Vaccine
by Sweta Jaiswal, FRM
Let's look at the ETFs that are well-poised to gain as Comirnaty's full FDA approval is likely to drive the vaccination rate.
Will CARZ ETF Gain Despite Mixed Auto Earnings?
by Sweta Jaiswal, FRM
Let's take a look at the impact of major automakers' earnings releases on automobile ETF amid the coronavirus crisis.
Nasdaq Tops 15K for First Time: 5 Best Stocks in the ETF
by Sweta Killa
The tech-heavy Nasdaq Composite Index topped 15,000 for the first time ever driven by continued strength in tech stocks.
High-Beta ETFs to Bet on Renewed Market Momentum
by Sweta Killa
High-beta ETFs seek to capitalize on consistent growth with market-beating returns.
AbbVie's (ABBV) Rinvoq Gets Approval for Eczema in Europe
by Zacks Equity Research
AbbVie's (ABBV) European approval for Rinvoq for atopic dermatitis marks the fourth EC-approved indication for the JAK inhibitor drug.
Stock Market News for Aug 25, 2021
by Zacks Equity Research
U.S. stocks continued their winning-run on Tuesday supported by the FDA¿¿¿s first full approval of COVID-19 vaccines.